Dental products company Dentsply Sirona (NASDAQ: XRAY) fell short of the market’s revenue expectations in Q3 2026, with sales falling 7.5% year on year to $836 million. The company’s full-year revenue guidance of $3.5 billion at the midpoint came in 1.9% below analysts’ estimates. Its non-GAAP profit of $0.29 per share was 6.2% below analysts’ consensus estimates.

Is now the time to buy XRAY? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Dentsply Sirona faced a difficult third quarter, as results missed Wall Street expectations and the market responded with a significant sell-off. Management pointed to persistent weakness across dental segments, particularly lingering impacts from the absence of Byte revenue, planned distributor inventory reductions, and continued pressure in both U.S. and international equipment sales. CEO Dan Scavilla acknowledged, "We are making progress, but our results are not yet where they need to be," highlighting that recent gains have yet to translate into widespread improvement. The company emphasized ongoing investment in clinical education, commercial execution, and innovation as core to its recovery efforts.

Looking ahead, Dentsply Sirona's updated guidance reflects a cautious stance, as management expects continued headwinds from European distributor inventory reductions, conflict in the Middle East, and inflation-driven cost pressures. The company plans to maintain investment in sales force expansion and clinical education, which are viewed as essential for long-term growth. CFO John Fortson noted that progress is being made on cost discipline and operational streamlining, but the outlook remains heavily dependent on successful execution of the Return-to-Growth Action Plan and stabilization in key markets.

Key insights from management’s remarks

Management cited the absence of Byte revenue, ongoing inventory adjustments, and mixed segment performance as the main drivers behind the quarterly miss, while highlighting early signs of progress in targeted U.S. businesses.

• Wellspect Healthcare momentum: The Wellspect business delivered double-digit sales growth, attributed to new product introductions and expanded U.S. market access, especially after recent Medicare coverage improvements.
• U.S. dental performance improving: Management observed 'green shoots' in the U.S. dental business, including double-digit growth in MIS value implants and increased adoption from expanded sales force coverage and clinician education.
• Inventory and Byte drag: Revenue was negatively impacted by the planned step-down in distributor inventory and the absence of Byte revenue, which together created a notable year-over-year headwind, particularly in the OAS (Ortho, Aligners, and Specialty) segment.
• EMEA and Middle East challenges: Sales in Europe, the Middle East, and Africa were hurt by distributor inventory reductions, competitive pricing pressures from lower-cost entrants, and deferred capital purchases amid regional conflict and uncertainty.
• Operational and accounting adjustments: A one-time $39 million gross profit benefit from accounting changes related to inventory consolidation was recognized, but management clarified this reflected multi-year adjustments rather than ongoing operating improvements.

Drivers of future performance

Dentsply Sirona’s outlook is shaped by continued investment in commercial execution and education against a backdrop of persistent market and cost challenges.

• Sales force and education investments: Management remains committed to expanding the sales force, particularly for MIS value implants, and ramping up clinician training initiatives to support product adoption and customer retention, aiming to drive recovery in underpenetrated segments.
• Geopolitical and market uncertainties: Ongoing conflict in the Middle East and continued European distributor inventory reductions are expected to weigh on results, with management noting that recovery in these regions may be gradual and is outside the company’s direct control.
• Cost management and efficiency: The company’s transformation office continues to advance a $120 million cost savings initiative for 2026, emphasizing tighter financial discipline and improved data systems to support more accurate forecasting and operational agility.

Catalysts in upcoming quarters

Looking ahead, the StockStory analyst team will be watching (1) whether sales force expansion and enhanced clinical education drive sustained gains in U.S. dental and implant growth, (2) signs of stabilization or recovery in EMEA and Middle East markets amid ongoing geopolitical and inventory headwinds, and (3) continued momentum and broader adoption of Wellspect’s new product portfolio. Progress on cost savings and operational streamlining will also be closely monitored as indicators of execution strength.

Dentsply Sirona currently trades at $8.62, down from $10.09 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Stocks that trumped tariffs

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.